We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-14.06%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$18.1M
(-9.1%)
Cap. Flow
+$21.8M
Cap. Flow
% of AUM
12.11%
Top 10 Holdings %
Top 10 Hldgs %
59.22%
Holding
45
New
6
Increased
14
Reduced
14
Closed
11
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
2.3
quarters
Top 20 Avg Time Held Equity + Options
2.6
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
2.3
quarters
Top 20 Avg Time Held Equity only
2.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$12.1M |
| 2 |
United Therapeutics
UTHR
|
+$10M |
| 3 |
MeiraGTx Holdings
MGTX
|
+$7.87M |
| 4 |
R1 RCM Inc. Common Stock
RCM
|
+$4.82M |
| 5 |
Guardant Health
GH
|
+$3.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$5.29M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$4.96M |
| 3 |
Zimmer Biomet
ZBH
|
+$4.87M |
| 4 |
Q32 Bio
QTTB
|
+$4.07M |
| 5 |
Indaptus Therapeutics
INDP
|
+$3.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.43% |
| 2 | Industrials | 2.03% |
| 3 | Miscellaneous | 0.55% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Zimmer Biomet
ZBH
$17.4B
| $17.6M | 9.75% |
131,840
-37,718
| -22% | -$4.87M |
2018 Q3
4 quarters
|
|
|
2
Bristol-Myers Squibb
BMY
$119B
| $15.5M | 8.58% |
304,900
-105,590
| -26% | -$4.96M |
2019 Q1
2 quarters
|
|
3
Kura Oncology
KURA
$855M
| $13.5M | 7.47% |
888,152
+20,342
| +2% | +$362K |
2018 Q2
5 quarters
|
|
|
4
uniQure
QURE
$1.42B
| $12.9M | 7.18% |
328,978
+208,978
| +174% | +$12.1M |
2019 Q2
1 quarter
|
|
|
5
United Therapeutics
UTHR
$23.1B
| $10.6M | 5.88% |
132,937
+124,337
| +1,446% | +$10M |
2019 Q2
1 quarter
|
|
|
HNGR
6
DELISTED
Hanger Inc.
HNGR
| $8.05M | 4.47% |
395,000
-96,685
| -20% | -$1.82M |
2018 Q3
4 quarters
|
|
7
UroGen Pharma
URGN
$1.82B
| $7.75M | 4.3% |
325,385
+64,457
| +25% | +$2.11M |
2019 Q1
2 quarters
|
|
|
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $7.47M | 4.14% |
163,133
-1,167
| -0.7% | -$65.6K |
2018 Q1
6 quarters
|
|
9
Centene
CNC
$34B
| $7.14M | 3.96% |
165,000
+38,500
| +30% | +$1.87M |
2017 Q4
7 quarters
|
|
10
Iovance Biotherapeutics
IOVA
$6.48B
| $6.3M | 3.49% |
346,149
-53,851
| -13% | -$1.19M |
2017 Q4
7 quarters
|
|
11
AC Immune
ACIU
$236M
| $6.18M | 3.43% |
1,248,453
+684,553
| +121% | +$3.67M |
2019 Q1
2 quarters
|
|
12
BioMarin Pharmaceuticals
BMRN
$10.6B
| $6.06M | 3.36% |
89,952
+38,752
| +76% | +$2.98M |
2018 Q1
6 quarters
|
|
|
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
| $6.01M | 3.33% |
2,515,072
-31,925
| -1% | -$85.7K |
2018 Q3
4 quarters
|
|
|
14
MeiraGTx Holdings
MGTX
$934M
| $5.39M | 2.99% |
+338,096
| New | +$7.87M |
2019 Q3
0 quarters
|
|
|
ALBO
15
DELISTED
Albireo Pharma Inc
ALBO
| $5.05M | 2.8% |
252,500
-827
| -0.3% | -$21.4K |
2018 Q3
4 quarters
|
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.03M | 2.79% |
62,591
-62,374
| -50% | -$5.29M |
2017 Q4
7 quarters
|
|
17
Aldeyra Therapeutics
ALDX
$48.3M
| $4.17M | 2.31% |
790,228
+92,307
| +13% | +$497K |
2018 Q4
3 quarters
|
|
|
18
DELISTED
R1 RCM Inc. Common Stock
RCM
| $3.65M | 2.03% |
+408,958
| New | +$4.82M |
2019 Q3
0 quarters
|
|
19
Humana
HUM
$51.2B
| $3.07M | 1.7% |
+12,000
| New | +$3.36M |
2019 Q3
0 quarters
|
|
20
AbbVie
ABBV
$502B
| $2.95M | 1.64% |
+39,000
| New | +$2.67M |
2019 Q3
0 quarters
|
|
|
21
Q32 Bio
QTTB
$236M
| $2.77M | 1.54% |
8,517
-11,986
| -58% | -$4.07M |
2019 Q2
1 quarter
|
|
22
Gyre Therapeutics
GYRE
$704M
| $2.74M | 1.52% |
74,421
+1,475
| +2% | +$79.5K |
2018 Q3
4 quarters
|
|
|
23
Guardant Health
GH
$21.8B
| $2.66M | 1.48% |
+41,700
| New | +$3.67M |
2019 Q3
0 quarters
|
|
|
ARQL
24
DELISTED
Arqule Inc
ARQL
| $2.62M | 1.45% |
364,797
+281,122
| +336% | +$2.64M |
2019 Q2
1 quarter
|
|
25
ADMA Biologics
ADMA
$2.35B
| $2.44M | 1.35% |
548,409
+362,688
| +195% | +$1.52M |
2019 Q2
1 quarter
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q3 2019 Portfolio in Review
As of Q3 2019, Prosight Management held 45 positions worth $180M, down 9.1% from $198M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Prosight Management deployed $21.8M of net new capital in Q3 2019, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was MeiraGTx Holdings: 338,096 shares worth $5.39M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $5.29M trimmed.
- Prosight Management's largest Q3 2019 buy was MeiraGTx Holdings: 338,096 shares worth $5.39M.
- Prosight Management added most to uniQure in Q3 2019, an estimated $12.1M increase.
- Prosight Management's biggest Q3 2019 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $5.29M.
- Prosight Management fully exited Indaptus Therapeutics in Q3 2019, selling an estimated $3.54M.
- Prosight Management's ten largest holdings make up 59% of its $180M portfolio in Q3 2019.
- Prosight Management opened 6 new positions and closed 11 in Q3 2019.
- Prosight Management's portfolio value fell 9.1% quarter-over-quarter to $180M.
Based on Prosight Management's 13F filing for Q3 2019, filed 14 Nov 2019.